Primary Objectives:
1. To determine the efficacy of Gleevec in patients with recurrent platinum-resistant,
taxane-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube
cancer whose tumor expresses either c-KIT, platelet-derived growth factor receptor
(PDGRF), or ABL.
2. To determine the nature and degree of toxicity of Gleevec in this cohort of patients.